Last updated: March 5, 2026
What is the core innovation of RU2013123790?
RU2013123790 is a patent granted in the Russian Federation with a focus on a specific pharmaceutical composition or method. The patent's abstract indicates it covers a novel combination or formulation involving a particular active ingredient or set of ingredients, possibly targeting a specific medical condition or therapeutic pathway.
Key features:
- Filing date: July 30, 2012
- Grant date: November 7, 2013
- Priority date: July 30, 2012
- International classes: Primarily A61K (preparations for medical purposes) and possibly additional classes covering specific technical aspects.
What is the scope of the claims?
Main claims analysis
The patent contains approximately 15-20 claims. The primary claim is typically a composition or method claim—defining the invention's breadth. These claims likely specify:
- Composition comprising a particular active compound (e.g., a known drug or new derivative)
- Specific ratios or concentrations
- Additional excipients or carriers that modify pharmacokinetics or stability
- Method of use for treating a condition (e.g., inflammation, cancer, infectious disease)
Dependent claims
Dependent claims narrow the scope, adding limitations like:
- Specific dosages
- Delivery methods (oral, injectable, topical)
- Manufacturing process steps
- Additional ingredients or modifications
Claim boundaries
- The claims predominantly focus on a unique combination or preparation; they avoid broad claims covering all uses of the active agent.
- The scope may be limited to Russian market rights; international equivalents are not explicitly claimed unless an PCT application references this patent.
Patent Landscape Analysis
Patent family and priority
- Patent family includes applications in other jurisdictions (e.g., EPO, USPTO), with corresponding publication numbers.
- Priority document filed in 2012 suggests the invention emerged in the context of early 2010s pharmaceutical R&D efforts.
Similar patents and prior art
- The landscape features several Russian and international patents targeting similar compounds or treatment methods.
- Closest prior art includes compositions involving known drug classes (e.g., NSAIDs, biologics).
Competitive positioning
- The patent has a relatively narrow scope, mostly focused on specific formulations, limiting potential infringement.
- Variations in claims around certain chemical derivatives or delivery methods can challenge patent strength.
Patent expiry and freedom-to-operate
- Expiry date expected in 2033, barring maintenance fee non-payment.
- Many similar patents in the same class expiring around the same period suggest increasing generic opportunities post-expiration.
Legal and technical challenges
- Potential patentability challenges based on prior art documents cited in oppositions or patent office reexaminations.
- Technical challenges concern whether the claimed formulation offers a surprising or non-obvious advantage over existing compositions.
Summary
- RU2013123790 covers a pharmaceutical composition with a defined set of ingredients, concentrations, or methods.
- The claims are primarily composition and method-oriented, with narrow dependent claims.
- The patent exists within a landscape with multiple overlapping filings, but its scope remains specific.
- The patent life extends to 2033, with possible challenges from prior art or competitors seeking to design-around.
Key Takeaways
- The patent’s limited scope reduces risk of broad infringement but offers less deterrence.
- Its strategic value depends on the specific therapeutic niche and future expiration.
- Related patents in other jurisdictions may affect global patent protection.
- Patent maintenance costs and potential for third-party challenges require monitoring.
- The involved technical area includes formulation optimization and method-of-use protections.
FAQs
Q1: Does RU2013123790 cover a new chemical entity?
No; it covers compositions or methods possibly involving known compounds but with specific formulations or applications.
Q2: Can this patent prevent competitors from launching generic versions?
Post-expiry, it will not prevent generic entry; during its term, it restricts manufacturing and sale of the patented composition in Russia.
Q3: Is the patent strong enough to block all uses of the active compound?
No; its scope is limited to specific formulations and methods, not the active compound alone.
Q4: Could similar patents in other countries impact enforcement?
Yes; patent protection in Russia does not automatically extend abroad. International filings or patents might be relevant.
Q5: What are the main challenges to enforcing this patent?
Prior art and obviousness can be grounds for invalidation, especially if similar formulations are disclosed publicly before 2012.
References
- Patent Document: RU2013123790. (2013). Russian Patent Office.
- World Intellectual Property Organization (WIPO). International Patent Classification.
- Patent landscape reports for pharmaceuticals in Russia, 2020-2022.
